JAK2 mutation and NGS myeloid mutation panel
Patients with PMF diagnosis had a JAK2-V617F mutation status known while the patients diagnosed with PMF after 2018 also had a myeloid NGS done. The controls had the myeloid NGS done en sure they did not have any clonal diseases. The genes included in our inhouse myeloid NGS mutation panel are: ABL1, ASXL1, ATM, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CDKN2A, CEBPA, CSF3R, DAXX, DNMT3A, EED, EGFR, ETV6, EZH2, FBXW7, FLT3, GATA1, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK1, JAK2, JAK3, KAT6A, KIT, KMT2A, KRAS, MPL, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PRPF40B, PTEN, PTPN11, RAD21, RB1, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SH2B3, SMARCB1, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1, U2AF2, WT1 and ZRSR2.